{"DataElement":{"publicId":"2485896","version":"1","preferredName":"First-Line Therapy Chemotherapy Regimen Type","preferredDefinition":"the type of first-line (standard) chemotherapy treatment plan.","longName":"FLTX_CT_RMG_TP","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2485893","version":"1","preferredName":"First-Line Therapy Chemotherapy Regimen","preferredDefinition":"information related to the preferred standard chemotherapy treatment plan for a particular condition.","longName":"FLTX_CT_RGM","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2485891","version":"1","preferredName":"First-Line Therapy Chemotherapy","preferredDefinition":"The preferred standard treatment for a particular condition.:The use of synthetic or naturally-occurring chemicals for the treatment of diseases.  Although this term may be used to describe any therapy involving the use of chemical-based agents, it is most commonly used to refer to the variety of chemical-based agents employed to treat cancer.  Cancer chemotherapy works by arresting or killing the growth and spread of cancer cells.  Because cancer cells usually divide much faster than normal cells, they are often very sensitive to the inhibitory actions of chemotherapeutic agents.  Chemotherapy may also include agents that enhance immune function or alter hormonal activity. (NCI04)","longName":"C45792:C15632","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"First-Line Therapy","conceptCode":"C45792","definition":"The preferred standard treatment for a particular condition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Chemotherapy","conceptCode":"C15632","definition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1593080E-5F8A-333C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-06","endDate":null,"createdBy":"ALAIS","dateCreated":"2006-06-06","modifiedBy":"ONEDATA","dateModified":"2006-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2224042","version":"1","preferredName":"Treatment_Regimen","preferredDefinition":"Treatment schedule for the pre-clinical trial / therapeutic experiment describing the dosages of the drug and the times of the treatment.","longName":"C15697","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F63F046F-540F-4E81-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-03","endDate":null,"createdBy":"UMLLOADER_CAMOD","dateCreated":"2005-05-03","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1593080E-5F98-333C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-06","endDate":null,"createdBy":"ALAIS","dateCreated":"2006-06-06","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2485894","version":"1","preferredName":"First-Line Therapy Chemotherapy Regimen Type","preferredDefinition":"the type of first-line chemotherapy treatment plan.","longName":"FLTX_XT_RGM_TP","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"45","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"FOLFOX","valueDescription":"Fluorouracil/Leucovorin Calcium/Oxaliplatin","ValueMeaning":{"publicId":"2579467","version":"1","preferredName":"Fluorouracil/Leucovorin Calcium/Oxaliplatin","longName":"2579467","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"FOLFOX Regimen","conceptCode":"C11197","definition":"One of several chemotherapy regimens that include leucovorin calcium (calcium folinate), 5-fluorouracil and oxaliplatin and which may be used in the treatment of advanced-stage and metastatic colorectal cancer. FOLFOX regimens differ in agent dosing and administration schedule and include FOLFOX 4, FOLFOX 6, modified FOLFOX 6 (mFOLFOX 6) and FOLFOX 7.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0378-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-06","endDate":null,"createdBy":"ALAIS","dateCreated":"2006-06-06","modifiedBy":"ONEDATA","dateModified":"2006-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"15931904-EC76-3603-E044-0003BA3F9857","beginDate":"2006-06-06","endDate":null,"createdBy":"ALAIS","dateCreated":"2006-06-06","modifiedBy":"ALAIS","dateModified":"2006-06-06","deletedIndicator":"No"},{"value":"OPTIMOX","valueDescription":"First-line therapy with FOLFOX-BEV, XELOX-BEV, or FLOX-BEV with discontinuation of oxaliplatin and then addition of fluoropyrimidine","ValueMeaning":{"publicId":"2579468","version":"1","preferredName":"First-line therapy with FOLFOX-BEV, XELOX-BEV, or FLOX-BEV with discontinuation of oxaliplatin and then addition of fluoropyrimidine","longName":"2579468","preferredDefinition":"First-line therapy with FOLFOX-BEV, XELOX-BEV, or FLOX-BEV with discontinuation of oxaliplatin and then addition of fluoropyrimidine","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0379-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-06","endDate":null,"createdBy":"ALAIS","dateCreated":"2006-06-06","modifiedBy":"ALAIS","dateModified":"2006-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1593662E-A272-34A1-E044-0003BA3F9857","beginDate":"2006-06-06","endDate":null,"createdBy":"ALAIS","dateCreated":"2006-06-06","modifiedBy":"ONEDATA","dateModified":"2006-06-06","deletedIndicator":"No"},{"value":"XELOX","valueDescription":"Capecitabine/Oxaliplatin/Bevacizumab (XELOX)","ValueMeaning":{"publicId":"2579469","version":"1","preferredName":"Capecitabine/Oxaliplatin/Bevacizumab (XELOX)","longName":"2579469","preferredDefinition":"Capecitabine/Oxaliplatin/Bevacizumab (XELOX)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-037A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-06","endDate":null,"createdBy":"ALAIS","dateCreated":"2006-06-06","modifiedBy":"ALAIS","dateModified":"2006-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"15932E0F-310B-34C7-E044-0003BA3F9857","beginDate":"2006-06-06","endDate":null,"createdBy":"ALAIS","dateCreated":"2006-06-06","modifiedBy":"ONEDATA","dateModified":"2006-06-06","deletedIndicator":"No"},{"value":"Pemetrexed and Cisplatin","valueDescription":"Pemetrexed-Cisplatin Regimen","ValueMeaning":{"publicId":"3557952","version":"1","preferredName":"Pemetrexed-Cisplatin Regimen","longName":"3557952","preferredDefinition":"A regimen consisting of pemetrexed and cisplatin used for the treatment of malignant mesothelioma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cisplatin/Pemetrexed Regimen","conceptCode":"C63788","definition":"A regimen consisting of pemetrexed and cisplatin that may be used for the treatment of malignant peritoneal and pleural mesothelioma, and non-small cell lung cancer (NSCLC).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C7502A41-7F0F-66C6-E040-BB89AD43459A","latestVersionIndicator":"Yes","beginDate":"2012-08-15","endDate":null,"createdBy":"LEUNGE","dateCreated":"2012-08-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C7502A41-7F28-66C6-E040-BB89AD43459A","beginDate":"2012-08-15","endDate":null,"createdBy":"LEUNGE","dateCreated":"2012-08-15","modifiedBy":"ONEDATA","dateModified":"2012-08-15","deletedIndicator":"No"},{"value":"Pemetrexed and Carboplatin","valueDescription":"Pemetrexed-Carboplatin Regimen","ValueMeaning":{"publicId":"3557953","version":"1","preferredName":"Pemetrexed-Carboplatin Regimen","longName":"3557953","preferredDefinition":"A regimen consisting of pemetrexed and carboplatin used for the treatment of malignant mesothelioma.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C7502A41-7F33-66C6-E040-BB89AD43459A","latestVersionIndicator":"Yes","beginDate":"2012-08-15","endDate":null,"createdBy":"LEUNGE","dateCreated":"2012-08-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C7502A41-7F4C-66C6-E040-BB89AD43459A","beginDate":"2012-08-15","endDate":null,"createdBy":"LEUNGE","dateCreated":"2012-08-15","modifiedBy":"ONEDATA","dateModified":"2012-08-15","deletedIndicator":"No"},{"value":"Cisplatin + pemetrexed + bevacizumab","valueDescription":"Cisplatin And Pemetrexed And Bevacizumab","ValueMeaning":{"publicId":"5810423","version":"1","preferredName":"Cisplatin And Pemetrexed And Bevacizumab","longName":"5810423","preferredDefinition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: A synthetic pyrimidine-based antifolate. Pemetrexed binds to and inhibits the enzyme thymidylate synthase (TS), which catalyses the methylation of 2'-deoxyuridine-5'-monophosphate (dUMP) to 2'-deoxythymidine-5'-monophosphate (dTMP), an essential precursor in DNA synthesis.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: A drug used to treat several types of cancer, including certain types of colorectal, lung, breast, and kidney cancers and glioblastoma. It is also being studied in the treatment of other types of cancer. Avastin binds to vascular endothelial growth factor (VEGF) and may prevent the growth of new blood vessels that tumors need to grow. It is a type of antiangiogenesis agent and a type of monoclonal antibody.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cisplatin","conceptCode":"C376","definition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Pemetrexed","conceptCode":"C61614","definition":"A synthetic pyrimidine-based antifolate. Pemetrexed binds to and inhibits the enzyme thymidylate synthase (TS), which catalyses the methylation of 2'-deoxyuridine-5'-monophosphate (dUMP) to 2'-deoxythymidine-5'-monophosphate (dTMP), an essential precursor in DNA synthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Bevacizumab","conceptCode":"C2039","definition":"A recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine.  Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4F028705-91D5-55C2-E053-F662850A0575","latestVersionIndicator":"Yes","beginDate":"2017-05-08","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-05-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4F028705-91EE-55C2-E053-F662850A0575","beginDate":"2017-05-08","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-05-08","modifiedBy":"ONEDATA","dateModified":"2017-05-08","deletedIndicator":"No"},{"value":"Carboplatin + pemetrexed + bevacizumab","valueDescription":"Carboplatin And Pemetrexed And Bevacizumab","ValueMeaning":{"publicId":"5810424","version":"1","preferredName":"Carboplatin And Pemetrexed And Bevacizumab","longName":"5810424","preferredDefinition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04): An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: A synthetic pyrimidine-based antifolate. Pemetrexed binds to and inhibits the enzyme thymidylate synthase (TS), which catalyses the methylation of 2'-deoxyuridine-5'-monophosphate (dUMP) to 2'-deoxythymidine-5'-monophosphate (dTMP), an essential precursor in DNA synthesis.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: A drug used to treat several types of cancer, including certain types of colorectal, lung, breast, and kidney cancers and glioblastoma. It is also being studied in the treatment of other types of cancer. Avastin binds to vascular endothelial growth factor (VEGF) and may prevent the growth of new blood vessels that tumors need to grow. It is a type of antiangiogenesis agent and a type of monoclonal antibody.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carboplatin","conceptCode":"C1282","definition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Pemetrexed","conceptCode":"C61614","definition":"A synthetic pyrimidine-based antifolate. Pemetrexed binds to and inhibits the enzyme thymidylate synthase (TS), which catalyses the methylation of 2'-deoxyuridine-5'-monophosphate (dUMP) to 2'-deoxythymidine-5'-monophosphate (dTMP), an essential precursor in DNA synthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Bevacizumab","conceptCode":"C2039","definition":"A recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine.  Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4F028705-91FE-55C2-E053-F662850A0575","latestVersionIndicator":"Yes","beginDate":"2017-05-08","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-05-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4F028705-9217-55C2-E053-F662850A0575","beginDate":"2017-05-08","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-05-08","modifiedBy":"ONEDATA","dateModified":"2017-05-08","deletedIndicator":"No"},{"value":"Carboplatin + pemetrexed","valueDescription":"Carboplatin And Pemetrexed","ValueMeaning":{"publicId":"5810425","version":"1","preferredName":"Carboplatin And Pemetrexed","longName":"5810425","preferredDefinition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04): An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: A synthetic pyrimidine-based antifolate. Pemetrexed binds to and inhibits the enzyme thymidylate synthase (TS), which catalyses the methylation of 2'-deoxyuridine-5'-monophosphate (dUMP) to 2'-deoxythymidine-5'-monophosphate (dTMP), an essential precursor in DNA synthesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carboplatin","conceptCode":"C1282","definition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Pemetrexed","conceptCode":"C61614","definition":"A synthetic pyrimidine-based antifolate. Pemetrexed binds to and inhibits the enzyme thymidylate synthase (TS), which catalyses the methylation of 2'-deoxyuridine-5'-monophosphate (dUMP) to 2'-deoxythymidine-5'-monophosphate (dTMP), an essential precursor in DNA synthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4F028705-9225-55C2-E053-F662850A0575","latestVersionIndicator":"Yes","beginDate":"2017-05-08","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-05-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4F028705-923E-55C2-E053-F662850A0575","beginDate":"2017-05-08","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-05-08","modifiedBy":"ONEDATA","dateModified":"2017-05-08","deletedIndicator":"No"},{"value":"Other, specify","valueDescription":"Other Specify","ValueMeaning":{"publicId":"4188777","version":"1","preferredName":"Other Specify","longName":"4188777","preferredDefinition":"Different than the one(s) previously specified or mentioned.: Be specific about something; define clearly.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Specify","conceptCode":"C25685","definition":"Be specific about something; define clearly.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3CC9DDB-CE4D-9879-E040-BB89AD430A03","latestVersionIndicator":"Yes","beginDate":"2014-03-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-03-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4F905588-1E52-18E1-E053-F662850A609C","beginDate":"2017-05-15","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-05-15","modifiedBy":"ONEDATA","dateModified":"2017-05-15","deletedIndicator":"No"},{"value":"ABVD","valueDescription":null,"ValueMeaning":{"publicId":"3377419","version":"1","preferredName":"ABVD Regimen","longName":"3377419","preferredDefinition":"A chemotherapy regimen consisting of doxorubicin hydrochloride (Adriamycin), bleomycin, vinblastine and dacarbazine, used alone or in combination with radiation therapy, for the primary treatment of Hodgkin lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ABVD Regimen","conceptCode":"C9509","definition":"A regimen consisting of doxorubicin, bleomycin, vinblastine and dacarbazine that can be used in the treatment of Hodgkin lymphoma (HL).","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8DFB740-1C13-299D-E040-BB89AD430A5E","latestVersionIndicator":"Yes","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F4C319EA-A488-3E17-E053-731AD00A3131","beginDate":"2023-02-15","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-02-15","modifiedBy":"FINCHAMB","dateModified":"2023-02-15","deletedIndicator":"No"},{"value":"AAVD","valueDescription":null,"ValueMeaning":{"publicId":"12571120","version":"1","preferredName":"AAVD Regimen","longName":"12571120v1.00","preferredDefinition":"A chemotherapy regimen consisting of brentuximab vedotin, doxorubicin, vinblastine and dacarbazine that can be used in the treatment of Hodgkin lymphoma (HL).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"AAVD Regimen","conceptCode":"C160563","definition":"A chemotherapy regimen consisting of brentuximab vedotin, doxorubicin, vinblastine and dacarbazine that can be used in the treatment of Hodgkin lymphoma (HL).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F4C31E21-99F1-3EA4-E053-731AD00A1D31","latestVersionIndicator":"Yes","beginDate":"2023-02-15","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-02-15","modifiedBy":"FINCHAMB","dateModified":"2023-02-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F4C31E21-99F2-3EA4-E053-731AD00A1D31","beginDate":"2023-02-15","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-02-15","modifiedBy":"FINCHAMB","dateModified":"2023-02-15","deletedIndicator":"No"},{"value":"Other","valueDescription":null,"ValueMeaning":{"publicId":"6431768","version":"1","preferredName":"Other","longName":"6431768v1.00","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"762A692A-EEF7-29A1-E053-F662850A9EA9","latestVersionIndicator":"Yes","beginDate":"2018-09-18","endDate":null,"createdBy":"WINCHC","dateCreated":"2018-09-18","modifiedBy":"GDEEN","dateModified":"2024-01-22","changeDescription":null,"administrativeNotes":"2023.2.1 Alt VM added per ticket request CADSR0001995. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F4C35162-9094-4544-E053-731AD00A8AF2","beginDate":"2023-02-15","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-02-15","modifiedBy":"FINCHAMB","dateModified":"2023-02-15","deletedIndicator":"No"},{"value":"NAVD","valueDescription":null,"ValueMeaning":{"publicId":"12662715","version":"1","preferredName":"N-AVD Regimen","longName":"12662715v1.00","preferredDefinition":"A regimen consisting of nivolumab, doxorubicin, vinblastine and dacarbazine that may be used for the treatment of Hodgkin lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"N-AVD Regimen","conceptCode":"C192740","definition":"A regimen consisting of nivolumab, doxorubicin, vinblastine and dacarbazine that may be used for the treatment of Hodgkin lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F4E6079B-A6FB-6915-E053-731AD00AAAD6","latestVersionIndicator":"Yes","beginDate":"2023-02-17","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-02-17","modifiedBy":"FINCHAMB","dateModified":"2023-02-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F4E6079B-A6FC-6915-E053-731AD00AAAD6","beginDate":"2023-02-17","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-02-17","modifiedBy":"FINCHAMB","dateModified":"2023-02-17","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"159318F4-2EC0-3479-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-06","endDate":null,"createdBy":"ALAIS","dateCreated":"2006-06-06","modifiedBy":"FINCHAMB","dateModified":"2023-02-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811871","version":"1","longName":"Colorectal","context":"CTEP"}]}],"AlternateNames":[{"name":"Alliance","type":"USED_BY","context":"Alliance"}],"ReferenceDocuments":[{"name":"CRF Text","type":"Preferred Question Text","description":"First-line chemotherapy regimen","url":null,"context":"CTEP"},{"name":"CRF Text1","type":"Alternate Question Text","description":"First-line systemic therapy plan","url":null,"context":"Alliance"},{"name":"ECOG-ACRIN - 1","type":"Alternate Question Text","description":"Frontline therapy received","url":null,"context":"ECOG-ACRIN"}],"origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"15932522-FA0D-34C1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-06","endDate":null,"createdBy":"ALAIS","dateCreated":"2006-06-06","modifiedBy":"FINCHAMB","dateModified":"2023-02-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}